Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Papillomavirus Infections 2Warts 1Uterine Cervical Dysplasia 1Infections 1High Grade Anal Canal Intraepithelial Neoplasia 1Condylomata Acuminata 1Cancer Survivor 1

Interventions

Voriconazole 2Daptomycin 2threonic acid 1telavancin 1telaprevir 1soybean oil, phospholipid emulsion 1plerixafor 1peginterferon alfa-2a 1human papillomavirus vaccine, L1 type 16, 18 1fludarabine phosphate 1Whole-Body Irradiation 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Tacrolimus 1Sulfamethoxazole 1Sirolimus 1Rituximab 1Ribavirin 1Peripheral Blood Stem Cell Transplantation 1Ofloxacin 1Methotrexate 1Melphalan 1Magnesium Sulfate 1Human Papillomavirus Recombinant Vaccine nonavalent 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Fluconazole 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Infections × Human Papillomavirus Recombinant Vaccine nonavalent × Clear all
NCT05496231 2025-02-03

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

GlaxoSmithKline

Phase 1/2 Completed
1,080 enrolled 28 charts
Gynecologic

Uterine Cervical Dysplasia, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡